To elucidate the translational implications of our findings, we investigated whether a synergistic anti-MM effect could be achieved by combining small molecules targeting NAT10 (Remodelin) and XPO1 (Selinexor) with BTZ. This evidence concerns the gene NAT10 and Miyoshi myopathy.